KALTF - Claritas inks deal with CMAX Clinical Research for early-stage R-107 study

Claritas Pharmaceuticals ([[KALTF]] +16.1%) has entered into an agreement with CMAX Clinical Research to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of R-107.The study is expected to begin enrollment of 32 healthy middle-aged volunteers in 4 ascending dose cohorts in early Q3 this year, and will have a duration of two months.R-107 is a liquid, nitric oxide-releasing compound that has demonstrated promising data in an animal study model for the treatment of pulmonary arterial hypertension ((PAH)).Claritas announced, earlier this month that it will enter into a separate License Agreement under which Salzman Group will grant exclusive, worldwide rights to develop R-107 for the treatment of PAH.

For further details see:

Claritas inks deal with CMAX Clinical Research for early-stage R-107 study